Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2022

Marron TU, Fiel MI, Hamon P, Fiaschi N, Kim E, Ward SC, et al. Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial. Lancet Gastroenterol Hepatol. 2022;7(3):219-229.

Park J, Foox J, Hether T, Danko DC, Warren S, Kim Y, et al. System-wide transcriptome damage and tissue identity loss in COVID-19 patients. Cell Rep Med. 2022;3(2):100522.

Raman R, Villefranc JA, Ullmann TM, Thiesmeyer J, Anelli V, Yao J, et al. Inhibition of FGF receptor blocks adaptive resistance to RET inhibition in CCDC6-RET-rearranged thyroid cancer. J Exp Med. 2022;219(6).

Pham K, Gottesdiener L, Simon MS, Trzebucki A, Maldarelli GA, Cisse B, et al. Corrigendum to: Meningovascular Syphilis Presenting as a Brain Mass in an Immunocompetent Male. Open Forum Infect Dis. 2022;9(1):ofab635.

Deshpande AS, Ulahannan N, Pendleton M, Dai X, Ly L, Behr JM, et al. Identifying synergistic high-order 3D chromatin conformations from genome-scale nanopore concatemer sequencing. Nat Biotechnol. 2022;40(10):1488-1499.

Magro CM, Mo JH, Telang G. Localized lymphomatoid papulosis: Unilesional lymphomatoid papulosis, regional lymphomatoid papulosis, and persistent agmination of lymphomatoid papulosis. Clin Dermatol. 2022;40(6):622-638.

Anderson KC, Cantley LC, Dalla-Favera R, Van Dang C, Diaz LA, DuBois RN, et al. The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission. Cancer Prev Res (Phila). 2022;15(11):705-712.

Bychkovsky BL, Li T, Sotelo J, Tayob N, Mercado J, Gomy I, et al. Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing Program. Clin Cancer Res. 2022;28(11):2349-2360.

Parra-Herran C, Khani F, Wobker SE. Gender distribution of editors and authors of reference textbooks in anatomic pathology: further edits are required. Mod Pathol. 2022;35(12):1784-1790.

Marzio A, Kurz E, Sahni JM, Di Feo G, Puccini J, Jiang S, et al. EMSY inhibits homologous recombination repair and the interferon response, promoting lung cancer immune evasion. Cell. 2022;185(1):169-183.e19.